This grant supports combined Phase 1/2a clinical trials testing new drugs (excluding amyloid/tau targets) for Alzheimer's, using a milestone-driven approach.
Funding for Alzheimer's drug development from pre-clinical to Phase I clinical trials to prevent, slow, or treat AD symptoms, excluding basic research and non-pharmacological interventions.
This grant supports academic and biotech researchers in developing new drugs to prevent, slow, or treat Alzheimer’s disease through preclinical and early-stage clinical research.
Use mouse models to test existing and investigational drugs for Alzheimer's; focus on drug repositioning and combo therapy development.
Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.
This grant funds early stage trials of new drugs and neuromodulatory devices for psychiatric disorders, aiming to de-risk and attract further funding.